Ramucirumab plus paclitaxel for gastric cancer in China
Mené sur 440 patients atteints d'un carcinome de l'estomac ou de la jonction oesogastrique de stade avancé, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, de l'ajout du ramucirumab au paclitaxel en traitement de seconde ligne
Globally, China is the country most affected by gastric cancer, accounting for 44%of the world's new gastric cancer cases (with >80% diagnosed at advanced stage) andfor 49% of all gastric cancer deaths, underscoring an enormous unmet need. Inhibition of VEGF receptor 2 (VEGFR-2) usingramucirumab in combination with paclitaxel has been standard treatment for patientswith previously treated advanced gastric cancer in North America, Europe, South Korea,Japan, and elsewhere, but not in China, where it has not been rigorously tested until now.
The Lancet Gastroenterology & Hepatology , commentaire, 2020